Bioquark Inc. and Revita Life Sciences to Collaborate on Regenerative Medicine Applications in Spinal Cord Injury

Bioquark Inc., a cutting edge life sciences company focused on the development of a novel biologic portfolio of products, services, and technologies for complex regeneration, disease reversion, and aging in humans, is entering a collaboration with India's Revita Life Sciences to advance translational opportunities in spinal cord injury repair.

Philadelphia, PA, February 06, 2016 --( Bioquark, Inc., ( a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, ( a biotechnology company focused on translational therapeutic applications of autologous adult stem cell therapy, have announced a collaboration to focus on novel combinatorial approaches to the restoration of function in spinal cord injury (SCI).

“We are very excited about this collaboration with Revita Life Sciences,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative medicine make for novel and transformational opportunities in spinal cord injury resolution.”

SCI refers to any injury to the spinal cord that is caused by trauma, and often causes changes in strength, body function and movement. SCI affects a patient’s physical, social, and psychological well-being and places a substantial burden on health care systems, families, and communities. It is estimated that the combined direct medical costs, disability support, and lost productivity of SCI surpass $20 billion annually in the U.S. alone.

While humans lack substantial regenerative capabilities in the CNS, many non-human species, such as amphibians, can quickly repair, regenerate and remodel substantial portions of their spinal cords following substantial trauma for complete structure and function resolution. Such complex regeneration is a result of multiple synergistic biologic pathways working together including the reprogramming of cells in damaged tissues, an appropriate histolytic response for extracellular matrix remodeling, and a balanced activation of the innate immune response to support ongoing morphogenesis.

“We look forward to working closely with Bioquark Inc. on this exciting initiative,” said Dr. Himanshu Bansal, Managing Director of Revita Life Sciences. “The ability to merge cellular and biologic approaches represents the next evolutionary step in achieving complete regeneration and return of full functionality in this devastating disease.

About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

About Revita Life Sciences
Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MD, PhD. who has spent over two decades developing novel MRI based classifications of spinal cord injuries as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, dural nerve grafts, nasal olfactory tissues, and omental transposition.
Bioquark Inc.
Ira S Pastor